Moreover, work from our laboratory has shown that the HER-2/neu(776–790) epitope (encompassing the HER-2/neu(780–788) sequence) functions as a potent tumor-immunogenic epitope capable of priming CD4+ T cells to synergize with autologous CD8+ T cells for enhanced cytotoxic antitumor activity [19,20]. Here, ERBB2 is linked to neoplasm.